Literature DB >> 17003342

Mechanisms of the depot specificity of peroxisome proliferator-activated receptor gamma action on adipose tissue metabolism.

Mathieu Laplante1, William T Festuccia, Geneviève Soucy, Yves Gélinas, Josée Lalonde, Joel P Berger, Yves Deshaies.   

Abstract

In this study, we aimed to establish the mechanisms whereby peroxisome proliferator-activated receptor gamma (PPARgamma) agonism brings about redistribution of fat toward subcutaneous depots and away from visceral fat. In rats treated with the full PPARgamma agonist COOH (30 mg x kg(-1) x day(-1)) for 3 weeks, subcutaneous fat mass was doubled and that of visceral fat was reduced by 30% relative to untreated rats. Uptake of triglyceride-derived nonesterified fatty acids was greatly increased in subcutaneous fat (14-fold) and less so in visceral fat (4-fold), with a concomitant increase, restricted to subcutaneous fat only, in mRNA levels of the uptake-, retention-, and esterification-promoting enzymes lipoprotein lipase, aP2, and diacylglycerol acyltransferase 1. Basal lipolysis and fatty acid recycling were stimulated by COOH in both subcutaneous fat and visceral fat, with no frank quantitative depot specificity. The agonist increased mRNA levels of enzymes of fatty acid oxidation and thermogenesis much more strongly in visceral fat than in subcutaneous fat, concomitantly with a stronger elevation in O2 consumption in the former than in the latter. Mitochondrial biogenesis was stimulated equally in both depots. These findings demonstrate that PPARgamma agonism redistributes fat by stimulating the lipid uptake and esterification potential in subcutaneous fat, which more than compensates for increased O2 consumption; conversely, lipid uptake is minimally altered and energy expenditure is greatly increased in visceral fat, with consequent reduction in fat accumulation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17003342     DOI: 10.2337/db06-0551

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  44 in total

1.  Meal fat storage in subcutaneous adipose tissue: comparison of pioglitazone and glipizide treatment of type 2 diabetes.

Authors:  Ananda Basu; Rita Basu; Vishwanath Pattan; Robert A Rizza; Michael D Jensen
Journal:  Obesity (Silver Spring)       Date:  2010-06-10       Impact factor: 5.002

2.  Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-gamma activation and function in lipid homeostasis and energy expenditure.

Authors:  Daozhong Jin; Hong Guo; So Young Bu; Yuanyuan Zhang; Jennifer Hannaford; Douglas G Mashek; Xiaoli Chen
Journal:  FASEB J       Date:  2010-10-25       Impact factor: 5.191

Review 3.  The contribution of vitamin A to autocrine regulation of fat depots.

Authors:  Rumana Yasmeen; Shanmugam M Jeyakumar; Barbara Reichert; Fangping Yang; Ouliana Ziouzenkova
Journal:  Biochim Biophys Acta       Date:  2011-06-13

4.  Proteasomal degradation of retinoid X receptor alpha reprograms transcriptional activity of PPARgamma in obese mice and humans.

Authors:  Bruno Lefebvre; Yacir Benomar; Aurore Guédin; Audrey Langlois; Nathalie Hennuyer; Julie Dumont; Emmanuel Bouchaert; Catherine Dacquet; Luc Pénicaud; Louis Casteilla; Francois Pattou; Alain Ktorza; Bart Staels; Philippe Lefebvre
Journal:  J Clin Invest       Date:  2010-04-01       Impact factor: 14.808

5.  Early exposure of the pregestational intrauterine and postnatal growth-restricted female offspring to a peroxisome proliferator-activated receptor-{gamma} agonist.

Authors:  Meena Garg; Manikkavasagar Thamotharan; Gerald Pan; Paul W N Lee; Sherin U Devaskar
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-12-15       Impact factor: 4.310

6.  Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue.

Authors:  Vanessa P Houde; Sophie Brûlé; William T Festuccia; Pierre-Gilles Blanchard; Kerstin Bellmann; Yves Deshaies; André Marette
Journal:  Diabetes       Date:  2010-03-18       Impact factor: 9.461

7.  Changes in visceral adipose tissue mitochondrial content with type 2 diabetes and daily voluntary wheel running in OLETF rats.

Authors:  Matthew J Laye; R Scott Rector; Shana O Warner; Scott P Naples; Aspen L Perretta; Grace M Uptergrove; M Harold Laughlin; John P Thyfault; Frank W Booth; Jamal A Ibdah
Journal:  J Physiol       Date:  2009-06-02       Impact factor: 5.182

8.  Control of adipogenesis by the autocrine interplays between angiotensin 1-7/Mas receptor and angiotensin II/AT1 receptor signaling pathways.

Authors:  Aung Than; Melvin Khee-Shing Leow; Peng Chen
Journal:  J Biol Chem       Date:  2013-04-16       Impact factor: 5.157

9.  Peroxisome proliferator-activated receptor-gamma regulates the expression and function of very-low-density lipoprotein receptor.

Authors:  Huan Tao; Srikanth Aakula; Naji N Abumrad; Tahar Hajri
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-10-27       Impact factor: 4.310

10.  Leucine modulation of mitochondrial mass and oxygen consumption in skeletal muscle cells and adipocytes.

Authors:  Xiaocun Sun; Michael B Zemel
Journal:  Nutr Metab (Lond)       Date:  2009-06-05       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.